Longitudinal voxel-based FDG PET assessment of chemotherapy effects on brain metabolism in lung cancer.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: non-small cell lung cancer (NSCLC) using a longitudinal, within-subject voxel-based F-FDG PET approach
I · Intervention 중재 / 시술
both pre- and post-chemotherapy FDG PET imaging were retrospectively enrolled
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] This within-subject FDG PET study provides longitudinal evidence that chemotherapy independently contributes to brain metabolic alterations in NSCLC patients, predominantly involving the frontal, temporal, and limbic regions. These findings highlight vulnerable neural substrates and underscore the clinical value of functional neuroimaging in cancer survivorship research.
OpenAlex 토픽 ·
Cancer-related cognitive impairment studies
Brain Metastases and Treatment
Lung Cancer Research Studies
[BACKGROUND] Chemotherapy-induced cognitive impairment (CICI) is a frequently reported complication in lung cancer patients, yet the underlying cerebral metabolic changes remain poorly characterized.
APA
Hao-Wen Cheng, Ing-Tsung Hsiao, et al. (2026). Longitudinal voxel-based FDG PET assessment of chemotherapy effects on brain metabolism in lung cancer.. Brain research bulletin, 237, 111817. https://doi.org/10.1016/j.brainresbull.2026.111817
MLA
Hao-Wen Cheng, et al.. "Longitudinal voxel-based FDG PET assessment of chemotherapy effects on brain metabolism in lung cancer.." Brain research bulletin, vol. 237, 2026, pp. 111817.
PMID
41819474 ↗
Abstract 한글 요약
[BACKGROUND] Chemotherapy-induced cognitive impairment (CICI) is a frequently reported complication in lung cancer patients, yet the underlying cerebral metabolic changes remain poorly characterized. This study aimed to evaluate chemotherapy-related alterations in brain glucose metabolism in patients with non-small cell lung cancer (NSCLC) using a longitudinal, within-subject voxel-based F-FDG PET approach.
[METHODS] Forty NSCLC patients who underwent both pre- and post-chemotherapy FDG PET imaging were retrospectively enrolled. Voxel-wise comparisons were performed using SPM12 to identify regional metabolic changes. Patients were stratified based on chemotherapy intensity (standard: ≥4 cycles; short-course: 1-3 cycles) and recovery interval (short: <6 months; long: ≥6 months), with subgroup and interaction analyses conducted accordingly.
[RESULTS] Compared with baseline, post-treatment scans revealed regional metabolic reductions, predominantly in the right thalamus, left frontal lobe, and bilateral temporal regions. Patients receiving standard chemotherapy exhibited more extensive metabolic reductions than those receiving short-course treatment, particularly in the bilateral temporal and cingulate regions. Furthermore, patients scanned within six months post-chemotherapy showed more pronounced reductions than those with longer recovery intervals, suggesting a potential trend of metabolic recovery over time. In contrast, patients with limited initial metabolic changes (i.e., short-course group) exhibited minimal changes across intervals.
[CONCLUSION] This within-subject FDG PET study provides longitudinal evidence that chemotherapy independently contributes to brain metabolic alterations in NSCLC patients, predominantly involving the frontal, temporal, and limbic regions. These findings highlight vulnerable neural substrates and underscore the clinical value of functional neuroimaging in cancer survivorship research.
[METHODS] Forty NSCLC patients who underwent both pre- and post-chemotherapy FDG PET imaging were retrospectively enrolled. Voxel-wise comparisons were performed using SPM12 to identify regional metabolic changes. Patients were stratified based on chemotherapy intensity (standard: ≥4 cycles; short-course: 1-3 cycles) and recovery interval (short: <6 months; long: ≥6 months), with subgroup and interaction analyses conducted accordingly.
[RESULTS] Compared with baseline, post-treatment scans revealed regional metabolic reductions, predominantly in the right thalamus, left frontal lobe, and bilateral temporal regions. Patients receiving standard chemotherapy exhibited more extensive metabolic reductions than those receiving short-course treatment, particularly in the bilateral temporal and cingulate regions. Furthermore, patients scanned within six months post-chemotherapy showed more pronounced reductions than those with longer recovery intervals, suggesting a potential trend of metabolic recovery over time. In contrast, patients with limited initial metabolic changes (i.e., short-course group) exhibited minimal changes across intervals.
[CONCLUSION] This within-subject FDG PET study provides longitudinal evidence that chemotherapy independently contributes to brain metabolic alterations in NSCLC patients, predominantly involving the frontal, temporal, and limbic regions. These findings highlight vulnerable neural substrates and underscore the clinical value of functional neuroimaging in cancer survivorship research.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Male
- Lung Neoplasms
- Female
- Fluorodeoxyglucose F18
- Middle Aged
- Carcinoma
- Non-Small-Cell Lung
- Aged
- Positron-Emission Tomography
- Brain
- Longitudinal Studies
- Retrospective Studies
- Antineoplastic Agents
- Chemotherapy-Related Cognitive Impairment
- Radiopharmaceuticals
- Brain Metabolism
- Chemotherapy
- Cognitive Impairment
- FDG PET
- NSCLC
- Voxel-Based Analysis
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.